MAP
PLRX icon

Madison Avenue Partners’s Pliant Therapeutics PLRX Stock Holding History

Madison Avenue Partners’s Portfolio PLRX Stock Details PLRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-2,230,012
Closed -$2.59M – 26
2025
Q2 		$2.59M Buy
2,230,012
+554,969
+33% +$784K 0.17% 23
2025
Q1 		$2.26M Buy
+1,675,043
New +$10.2M 0.19% 18

Other funds holding PLRX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

Madison Avenue Partners's PLRX Position: Q3 2025 in Review

Madison Avenue Partners sold out of Pliant Therapeutics (PLRX) in Q3 2025, closing a stake of 2,230,012 shares — an estimated $2.59M sold.

Madison Avenue Partners first reported a position in PLRX in Q1 2025 and held it in 2 quarters. The position peaked at $2.59M in Q2 2025. 99 funds tracked by Wall St. Rank hold PLRX as of Q3 2025.

  • Madison Avenue Partners reported no remaining Pliant Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Madison Avenue Partners sold 2,230,012 Pliant Therapeutics shares in Q3 2025, an estimated $2.59M.
  • Madison Avenue Partners first reported a position in Pliant Therapeutics in Q1 2025 and held it in 2 quarters.
  • Madison Avenue Partners's Pliant Therapeutics position peaked at $2.59M in Q2 2025.
  • 99 funds tracked by Wall St. Rank held Pliant Therapeutics as of Q3 2025.

Based on Madison Avenue Partners's 13F filing for Q3 2025, filed 14 Nov 2025.